As of 2025-07-21, the Intrinsic Value of Trident Texofab Ltd (540726.BO) is 136.09 INR. This 540726.BO valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 214.75 INR, the upside of Trident Texofab Ltd is -36.60%.
The range of the Intrinsic Value is 107.02 - 184.47 INR
Based on its market price of 214.75 INR and our intrinsic valuation, Trident Texofab Ltd (540726.BO) is overvalued by 36.60%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 107.02 - 184.47 | 136.09 | -36.6% |
| DCF (Growth 10y) | 176.58 - 291.77 | 220.15 | 2.5% |
| DCF (EBITDA 5y) | 241.41 - 305.03 | 270.26 | 25.8% |
| DCF (EBITDA 10y) | 305.75 - 411.49 | 353.11 | 64.4% |
| Fair Value | 41.83 - 41.83 | 41.83 | -80.52% |
| P/E | 32.96 - 98.47 | 65.11 | -69.7% |
| EV/EBITDA | 65.19 - 128.84 | 90.50 | -57.9% |
| EPV | 32.32 - 43.32 | 37.82 | -82.4% |
| DDM - Stable | 10.18 - 21.60 | 15.89 | -92.6% |
| DDM - Multi | 86.15 - 145.14 | 108.41 | -49.5% |
| Market Cap (mil) | 3,221.25 |
| Beta | -0.42 |
| Outstanding shares (mil) | 15.00 |
| Enterprise Value (mil) | 3,485.71 |
| Market risk premium | 8.31% |
| Cost of Equity | 12.24% |
| Cost of Debt | 5.00% |
| WACC | 11.56% |